Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Inclusion Criteria:

* Patients with histologic diagnosis of PTCL according to the WHO-REAL classification;
* Age \> 18 years;
* Relapsed (³1) or refractory to conventional chemotherapy/radiotherapy;
* Stage I-IV according to the Ann Arbor staging System;
* Performance status \<2;
* Adequate bone marrow reserve: platelets \>50 x 10(9)/L, absolute neutrophil count
* (ANC) \> 1.0 x 10(9)/L, hemoglobin \>8 g/d;
* Normal renal and hepatic functions;
* Negative HIV, HCV, and HBV status;
* Informed consent prior to registration on study

Exclusion Criteria:

* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
* Use of any other experimental drug or therapy within 28 days of baseline.
* Known hypersensitivity to thalidomide.
* The development of erythema if characterized by a desquamating rash while taking thalidomide or similar drugs.
* Any prior use of lenalidomide.
* Concurrent use of other anti-cancer agents or treatments.
* Known positive for HIV or infectious hepatitis, type A, B or C.